600713 南京医药
2026/09 - 九个月
人民幣(K¥)
与去年同期
比较
2025/12
人民幣(K¥)
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
营业总收入41,686,9511.34%54,963,27753,696,17453,589,66550,221,564
减:营业总成本40,821,6371.18%53,921,72352,651,38552,645,43949,186,223
    其中:营业成本39,132,5941.15%51,580,94150,323,07850,276,36246,962,430
               财务费用331,527-4.11%461,819515,588534,751435,170
               资产减值损失(6,199)15.53%(25,113)(18,267)(6,248)(6,771)
公允价值变动收益374-58.36%283------
投资收益4,867325.43%4,7944,0188,581(48,645)
    其中:对联营企业和合营企业的投资收益(1,693)-37.88%(1,671)5856,062(519)
营业利润771,15811.53%1,160,1061,023,4041,007,443934,323
利润总额760,2187.29%1,157,6281,003,395978,068906,012
减:所得税费用215,37720.46%324,959260,275265,259190,092
净利润544,8412.85%832,669743,120712,809715,920
减:非控股权益129,6211.44%207,834172,492134,983120,252
股东净利润415,2203.30%624,835570,628577,826595,668

市场价值指针
每股收益 (元) *0.3193.57%0.4800.4380.4450.475
每股派息 (元) *0.090--0.1700.1700.1600.140
每股净资产 (元) *5.5434.14%5.4845.2164.9124.579
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容